Loading...
The goal of finding the “right therapy for the right patient” has been the Holy Grail of targeted therapeutics. However, tailoring therapy for solid cancers might prove to be extremely complicated, given that intratumor heterogeneity might promote tumor adaptation and thereby hinder strategies based on single tumor-biopsy sampling methods used in most personalized medicine approaches.
To study intratumor heterogeneity, investigators examined spatially separated biopsy samples from four consecutive patients with metastatic renal carcinoma who were included in the E-PREDICT trial of everolimus, a mammalian target of rapamycin (mTOR) inhibitor. Biopsy samples were obtained before 6 weeks of treatment with everolimus. After a 1-week washout peri…